Display options
Cite
Versteeg R, van der Minne C, Plomp A, et al. N-myc expression switched off and class I human leukocyte antigen expression switched on after somatic cell fusion of neuroblastoma cells. Mol Cell Biol. 1990;10(10):5416-23doi: 10.1128/mcb.10.10.5416-5423.1990.
Versteeg, R., van der Minne, C., Plomp, A., Sijts, A., van Leeuwen, A., & Schrier, P. (1990). N-myc expression switched off and class I human leukocyte antigen expression switched on after somatic cell fusion of neuroblastoma cells. Molecular and cellular biology, 10(10), 5416-23. https://doi.org/10.1128/mcb.10.10.5416-5423.1990
Versteeg, R, et al. "N-myc expression switched off and class I human leukocyte antigen expression switched on after somatic cell fusion of neuroblastoma cells." Molecular and cellular biology vol. 10,10 (1990): 5416-23. doi: https://doi.org/10.1128/mcb.10.10.5416-5423.1990
Versteeg R, van der Minne C, Plomp A, Sijts A, van Leeuwen A, Schrier P. N-myc expression switched off and class I human leukocyte antigen expression switched on after somatic cell fusion of neuroblastoma cells. Mol Cell Biol. 1990 Oct;10(10):5416-23. doi: 10.1128/mcb.10.10.5416-5423.1990. PMID: 2204814; PMCID: PMC361245.
Copy Download .nbib Format: NLM
Share it on
Full text links
Atypon Free PMC Article

Mol Cell Biol. 1990 Oct;10(10):5416-23. doi: 10.1128/mcb.10.10.5416-5423.1990.

N-myc expression switched off and class I human leukocyte antigen expression switched on after somatic cell fusion of neuroblastoma cells.

Molecular and cellular biology

R Versteeg, C van der Minne, A Plomp, A Sijts, A van Leeuwen, P Schrier

Affiliations

  1. Department of Clinical Oncology, University Hospital Leiden, The Netherlands.

PMID: 2204814 PMCID: PMC361245 DOI: 10.1128/mcb.10.10.5416-5423.1990
Free PMC Article

Abstract

Neuroblastomas often show amplification and high expression of the N-myc oncogene. N-myc expression could be explained as a consequence of gene amplification, but an alternative possibility is that expression primarily results from the inactivation or loss of some factor that normally represses the N-myc gene. To test this idea, we fused N-myc-overexpressing neuroblastoma cell lines with lines that do not express N-myc. In the resulting hybrids, N-myc expression turned out to be switched off, although amplified N-myc copies were still present. This suggests that N-myc overexpression in neuroblastomas results, at least in part, from the inactivation of a suppressor gene that is present in normal cells. In rat neuroblastomas, it has been found that N-myc can switch off class I major histocompatibility complex (MHC) expression. Therefore, we analyzed in our hybrid cells whether suppression of N-myc results in reexpression of human class I MHC genes. Because this was found to be the case, the picture emerges of a hierarchic pathway that connects a putative tumor-suppressor gene with the expression of N-myc and consequently of class I MHC, thus affecting the potential immunogenic properties of neuroblastomas.

Cited by

References

  1. Cell. 1978 May;14(1):9-20 - PubMed
  2. Cancer. 1977 Nov;40(5):2256-63 - PubMed
  3. Adv Immunol. 1979;27:51-177 - PubMed
  4. Methods Enzymol. 1980;65(1):826-39 - PubMed
  5. Eur J Biochem. 1980 Jun;107(2):303-14 - PubMed
  6. Cancer. 1980 Mar 1;45(5):833-9 - PubMed
  7. Cancer Res. 1981 Nov;41(11 Pt 1):4678-86 - PubMed
  8. J Immunol. 1983 May;130(5):2471-8 - PubMed
  9. Nature. 1983 Sep 15-21;305(5931):245-8 - PubMed
  10. Cell. 1984 Jul;37(3):705-13 - PubMed
  11. N Engl J Med. 1984 Aug 30;311(9):584-5 - PubMed
  12. Science. 1984 Dec 14;226(4680):1335-7 - PubMed
  13. J Immunol. 1985 Jul;135(1):242-6 - PubMed
  14. N Engl J Med. 1985 Oct 31;313(18):1111-6 - PubMed
  15. Nature. 1986 Feb 20-26;319(6055):675-8 - PubMed
  16. Immunogenetics. 1986;23(3):164-71 - PubMed
  17. Cell. 1986 Dec 5;47(5):667-74 - PubMed
  18. J Immunol. 1987 Feb 15;138(4):1178-83 - PubMed
  19. Immunogenetics. 1987;25(5):313-22 - PubMed
  20. J Clin Invest. 1987 Sep;80(3):804-11 - PubMed
  21. Br J Cancer. 1988 Jan;57(1):121-6 - PubMed
  22. EMBO J. 1988 Apr;7(4):1023-9 - PubMed
  23. Prog Clin Biol Res. 1988;271:291-306 - PubMed
  24. Prog Clin Biol Res. 1988;271:41-9 - PubMed
  25. Prog Clin Biol Res. 1988;271:57-69 - PubMed
  26. J Natl Cancer Inst. 1988 Dec 21;80(20):1633-7 - PubMed
  27. Immunogenetics. 1989;29(1):25-32 - PubMed
  28. Proc Natl Acad Sci U S A. 1989 Apr;86(7):2361-4 - PubMed
  29. Eur J Immunol. 1989 Mar;19(3):447-51 - PubMed
  30. EMBO J. 1989 Mar;8(3):749-55 - PubMed
  31. Proc Natl Acad Sci U S A. 1989 May;86(10):3753-7 - PubMed
  32. J Exp Med. 1989 Sep 1;170(3):621-35 - PubMed
  33. J Immunol. 1989 Dec 15;143(12):4292-9 - PubMed
  34. J Immunol. 1989 Dec 15;143(12):4331-7 - PubMed
  35. Am J Clin Pathol. 1969 Jan;51(1):126-36 - PubMed
  36. Cancer Res. 1970 Aug;30(8):2110-8 - PubMed
  37. Cancer Res. 1976 Sep;36(9 pt.1):3094-100 - PubMed
  38. Proc Natl Acad Sci U S A. 1979 Oct;76(10):5239-42 - PubMed

Substances

MeSH terms

Publication Types

LinkOut - more resources